Pharmacotherapy for ossification of the spinal ligaments

Clinical trial of disodium (1-hydroxyethylidene) diphosphonate to inhibit progression of ossification of the posterior longitudinal ligament in the cervical spine after posterior decompression surgery

Kazuo Yonenobu, Kensei Nagata, Kuniyoshi Abumi, Yoshiaki Toyama, Sinya Kawai

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Introduction With advances in surgical techniques for ossification of the posterior longitudinal ligament (OPLL), the surgical results of both anterior and posterior procedures have been improved. However, the regression of neurological symptoms due to progression of OPLL during the follow-up period has been reported, and preventing progression of OPLL after surgery is an issue to be solved urgently from the viewpoint of stable long-term surgical results. Fortunately, the incidence of neurological symptom appearance is relatively low, but the incidence of postoperative progression of OPLL during the follow-up period is reported to be high after both anterior and posterior decompression. After anterior procedures, the reported incidence varies from 31% to 36% [1,2]. After posterior procedures, including laminectomy [3] and laminoplasty [4-7], the incidence is reported to be high (40%-100%). Etidronate disodium-chemical name: disodium (1- hydroxyethylidene) diphosphonate, or EHDP-has the ability to adsorb onto hydroxyapatite and its noncrystalline precursors chemically and to inhibit aggregation, growth, and calcifi cation of these crystals [8]. It is therefore widely used to treat heterotopic ossification in clinical practice. Considering that OPLL is a form of heterotopic ossification, we hypothesized that EHDP has the therapeutic potential to inhibit the progress of OPLL because of its calcifi cation-inhibitory effect. The preventive effect of EHDP on postoperative ossification was evaluated by other investigators in 66 patients with OPLL of the cervical spine who underwent posterior decompression and were treated with a cyclic regimen of oral EHDP at 200-1000 mg daily for 3 months followed by treatment withdrawal for 3 months; this regimen was repeated for 2 years [9]. At study termination, signifi cant suppression of ossification was observed with EHDP 1000 mg/day compared with control treatment; moreover, at the 1-year follow-up there was no progression of ossification. These clinical fi ndings led us to conduct the present study: a randomized dose-ranging, double-blind, placebo-controlled, parallel-group, multicenter study (study 1). Simultaneous with study 1, a retrospective study (study 2) was conducted, as the target disease is rare and the size of the patient population in study 1 was considered to be small and likely to limit the power to detect signifi cant group differences. The effi cacy of EHDP in inhibiting progression of OPLL after posterior decompression was evaluated based on the combined data from studies 1 and 2. We also conducted a pilot study of EHDP to reconfi rm the results of the previous clinical trial.

Original languageEnglish
Title of host publicationOPLL: Ossification of the Posterior Longitudinal Ligament
PublisherSpringer Japan
Pages169-176
Number of pages8
ISBN (Print)4431325611, 9784431325611
DOIs
Publication statusPublished - 2006

Fingerprint

Ossification of Posterior Longitudinal Ligament
Etidronic Acid
Diphosphonates
Decompression
Ligaments
Osteogenesis
Spine
Clinical Trials
Drug Therapy
Heterotopic Ossification
Incidence
Cations
Laminectomy
Durapatite
Rare Diseases
Population Density
Multicenter Studies
Names
Therapeutics
Retrospective Studies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pharmacotherapy for ossification of the spinal ligaments : Clinical trial of disodium (1-hydroxyethylidene) diphosphonate to inhibit progression of ossification of the posterior longitudinal ligament in the cervical spine after posterior decompression surgery. / Yonenobu, Kazuo; Nagata, Kensei; Abumi, Kuniyoshi; Toyama, Yoshiaki; Kawai, Sinya.

OPLL: Ossification of the Posterior Longitudinal Ligament. Springer Japan, 2006. p. 169-176.

Research output: Chapter in Book/Report/Conference proceedingChapter

Yonenobu, Kazuo ; Nagata, Kensei ; Abumi, Kuniyoshi ; Toyama, Yoshiaki ; Kawai, Sinya. / Pharmacotherapy for ossification of the spinal ligaments : Clinical trial of disodium (1-hydroxyethylidene) diphosphonate to inhibit progression of ossification of the posterior longitudinal ligament in the cervical spine after posterior decompression surgery. OPLL: Ossification of the Posterior Longitudinal Ligament. Springer Japan, 2006. pp. 169-176
@inbook{78ce0287dfe341d59fe9286d63494fd2,
title = "Pharmacotherapy for ossification of the spinal ligaments: Clinical trial of disodium (1-hydroxyethylidene) diphosphonate to inhibit progression of ossification of the posterior longitudinal ligament in the cervical spine after posterior decompression surgery",
abstract = "Introduction With advances in surgical techniques for ossification of the posterior longitudinal ligament (OPLL), the surgical results of both anterior and posterior procedures have been improved. However, the regression of neurological symptoms due to progression of OPLL during the follow-up period has been reported, and preventing progression of OPLL after surgery is an issue to be solved urgently from the viewpoint of stable long-term surgical results. Fortunately, the incidence of neurological symptom appearance is relatively low, but the incidence of postoperative progression of OPLL during the follow-up period is reported to be high after both anterior and posterior decompression. After anterior procedures, the reported incidence varies from 31{\%} to 36{\%} [1,2]. After posterior procedures, including laminectomy [3] and laminoplasty [4-7], the incidence is reported to be high (40{\%}-100{\%}). Etidronate disodium-chemical name: disodium (1- hydroxyethylidene) diphosphonate, or EHDP-has the ability to adsorb onto hydroxyapatite and its noncrystalline precursors chemically and to inhibit aggregation, growth, and calcifi cation of these crystals [8]. It is therefore widely used to treat heterotopic ossification in clinical practice. Considering that OPLL is a form of heterotopic ossification, we hypothesized that EHDP has the therapeutic potential to inhibit the progress of OPLL because of its calcifi cation-inhibitory effect. The preventive effect of EHDP on postoperative ossification was evaluated by other investigators in 66 patients with OPLL of the cervical spine who underwent posterior decompression and were treated with a cyclic regimen of oral EHDP at 200-1000 mg daily for 3 months followed by treatment withdrawal for 3 months; this regimen was repeated for 2 years [9]. At study termination, signifi cant suppression of ossification was observed with EHDP 1000 mg/day compared with control treatment; moreover, at the 1-year follow-up there was no progression of ossification. These clinical fi ndings led us to conduct the present study: a randomized dose-ranging, double-blind, placebo-controlled, parallel-group, multicenter study (study 1). Simultaneous with study 1, a retrospective study (study 2) was conducted, as the target disease is rare and the size of the patient population in study 1 was considered to be small and likely to limit the power to detect signifi cant group differences. The effi cacy of EHDP in inhibiting progression of OPLL after posterior decompression was evaluated based on the combined data from studies 1 and 2. We also conducted a pilot study of EHDP to reconfi rm the results of the previous clinical trial.",
author = "Kazuo Yonenobu and Kensei Nagata and Kuniyoshi Abumi and Yoshiaki Toyama and Sinya Kawai",
year = "2006",
doi = "10.1007/978-4-431-32563-5_23",
language = "English",
isbn = "4431325611",
pages = "169--176",
booktitle = "OPLL: Ossification of the Posterior Longitudinal Ligament",
publisher = "Springer Japan",

}

TY - CHAP

T1 - Pharmacotherapy for ossification of the spinal ligaments

T2 - Clinical trial of disodium (1-hydroxyethylidene) diphosphonate to inhibit progression of ossification of the posterior longitudinal ligament in the cervical spine after posterior decompression surgery

AU - Yonenobu, Kazuo

AU - Nagata, Kensei

AU - Abumi, Kuniyoshi

AU - Toyama, Yoshiaki

AU - Kawai, Sinya

PY - 2006

Y1 - 2006

N2 - Introduction With advances in surgical techniques for ossification of the posterior longitudinal ligament (OPLL), the surgical results of both anterior and posterior procedures have been improved. However, the regression of neurological symptoms due to progression of OPLL during the follow-up period has been reported, and preventing progression of OPLL after surgery is an issue to be solved urgently from the viewpoint of stable long-term surgical results. Fortunately, the incidence of neurological symptom appearance is relatively low, but the incidence of postoperative progression of OPLL during the follow-up period is reported to be high after both anterior and posterior decompression. After anterior procedures, the reported incidence varies from 31% to 36% [1,2]. After posterior procedures, including laminectomy [3] and laminoplasty [4-7], the incidence is reported to be high (40%-100%). Etidronate disodium-chemical name: disodium (1- hydroxyethylidene) diphosphonate, or EHDP-has the ability to adsorb onto hydroxyapatite and its noncrystalline precursors chemically and to inhibit aggregation, growth, and calcifi cation of these crystals [8]. It is therefore widely used to treat heterotopic ossification in clinical practice. Considering that OPLL is a form of heterotopic ossification, we hypothesized that EHDP has the therapeutic potential to inhibit the progress of OPLL because of its calcifi cation-inhibitory effect. The preventive effect of EHDP on postoperative ossification was evaluated by other investigators in 66 patients with OPLL of the cervical spine who underwent posterior decompression and were treated with a cyclic regimen of oral EHDP at 200-1000 mg daily for 3 months followed by treatment withdrawal for 3 months; this regimen was repeated for 2 years [9]. At study termination, signifi cant suppression of ossification was observed with EHDP 1000 mg/day compared with control treatment; moreover, at the 1-year follow-up there was no progression of ossification. These clinical fi ndings led us to conduct the present study: a randomized dose-ranging, double-blind, placebo-controlled, parallel-group, multicenter study (study 1). Simultaneous with study 1, a retrospective study (study 2) was conducted, as the target disease is rare and the size of the patient population in study 1 was considered to be small and likely to limit the power to detect signifi cant group differences. The effi cacy of EHDP in inhibiting progression of OPLL after posterior decompression was evaluated based on the combined data from studies 1 and 2. We also conducted a pilot study of EHDP to reconfi rm the results of the previous clinical trial.

AB - Introduction With advances in surgical techniques for ossification of the posterior longitudinal ligament (OPLL), the surgical results of both anterior and posterior procedures have been improved. However, the regression of neurological symptoms due to progression of OPLL during the follow-up period has been reported, and preventing progression of OPLL after surgery is an issue to be solved urgently from the viewpoint of stable long-term surgical results. Fortunately, the incidence of neurological symptom appearance is relatively low, but the incidence of postoperative progression of OPLL during the follow-up period is reported to be high after both anterior and posterior decompression. After anterior procedures, the reported incidence varies from 31% to 36% [1,2]. After posterior procedures, including laminectomy [3] and laminoplasty [4-7], the incidence is reported to be high (40%-100%). Etidronate disodium-chemical name: disodium (1- hydroxyethylidene) diphosphonate, or EHDP-has the ability to adsorb onto hydroxyapatite and its noncrystalline precursors chemically and to inhibit aggregation, growth, and calcifi cation of these crystals [8]. It is therefore widely used to treat heterotopic ossification in clinical practice. Considering that OPLL is a form of heterotopic ossification, we hypothesized that EHDP has the therapeutic potential to inhibit the progress of OPLL because of its calcifi cation-inhibitory effect. The preventive effect of EHDP on postoperative ossification was evaluated by other investigators in 66 patients with OPLL of the cervical spine who underwent posterior decompression and were treated with a cyclic regimen of oral EHDP at 200-1000 mg daily for 3 months followed by treatment withdrawal for 3 months; this regimen was repeated for 2 years [9]. At study termination, signifi cant suppression of ossification was observed with EHDP 1000 mg/day compared with control treatment; moreover, at the 1-year follow-up there was no progression of ossification. These clinical fi ndings led us to conduct the present study: a randomized dose-ranging, double-blind, placebo-controlled, parallel-group, multicenter study (study 1). Simultaneous with study 1, a retrospective study (study 2) was conducted, as the target disease is rare and the size of the patient population in study 1 was considered to be small and likely to limit the power to detect signifi cant group differences. The effi cacy of EHDP in inhibiting progression of OPLL after posterior decompression was evaluated based on the combined data from studies 1 and 2. We also conducted a pilot study of EHDP to reconfi rm the results of the previous clinical trial.

UR - http://www.scopus.com/inward/record.url?scp=44649092163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44649092163&partnerID=8YFLogxK

U2 - 10.1007/978-4-431-32563-5_23

DO - 10.1007/978-4-431-32563-5_23

M3 - Chapter

SN - 4431325611

SN - 9784431325611

SP - 169

EP - 176

BT - OPLL: Ossification of the Posterior Longitudinal Ligament

PB - Springer Japan

ER -